

2016 Antibiogram Outpatient Community Providers (January-December)

Relative Total Cost Per Day PO ¹	\$	\$\$\$	\$	\$\$\$	\$	\$
Gram Negative Organisms Legend: • Susceptible Reported as % • (Maximum # strains tested) ↑ > 5% increase in Susceptibility from Previous Year ↓ > 5% decrease in Susceptibility from Previous Year	Cefazolin ³	Ceftriaxone	Ciprofloxacin	Levofloxacin	Trimethoprim/sulfa	Nitrofurantoin Urinary Tract Infections only
<i>Escherichia coli</i> (1764)	70 ³	94	78	78	81	96
<i>Enterobacter species</i> ² (89)	0	85	98	99	90	41
<i>Klebsiella species</i> (424)	63 ³ ↑	85	84 ↑	85 ↑	81	43 ↑
<i>Proteus species</i> (147)	82 ³	99	71 ↑	76 ↑	77 ↑	0
<i>Pseudomonas aeruginosa</i> (180)	-	-	79	74	-	-

Relative Total Cost Per Day PO ¹	\$	\$	\$	\$	\$	\$\$\$	\$	\$	\$	\$	\$	\$
Gram Positive Organisms Legend: • Susceptible Reported as % • (Maximum # strains tested) ↑ > 5% increase in Susceptibility from Previous Year ↓ > 5% decrease in Susceptibility from Previous Year	Ceftriaxone Non-meningitis	Ceftriaxone Meningitis	Clindamycin	Erythromycin	Levofloxacin	Linezolid	Penicillin	Penicillin Non-meningitis	Penicillin Meningitis	Tetracycline	Trimethoprim/sulfa	Nitrofurantoin Urinary Tract Infections only
<i>Staphylococcus aureus</i> (552)	-	-	73	35 ↓	72	100	0	-	-	97	97	100
<i>Staphylococcus coagulase negative</i> (172)	-	-	65	46	65 ↓	100	0	-	-	85 ↓	77 ↑	99
<i>Enterococcus faecalis</i> (194)	-	-	-	-	71	100	98	-	-	-	-	100
<i>Enterococcus faecium</i> ^{2,5} (15)	-	-	-	-	3/15	100	2/15	-	-	-	-	2/15
<i>Streptococcus pneumoniae</i> ² (44)	98	82	77	55	100	100	-	98	57	75	-	-
<i>Streptococcus agalactiae</i> (Group B) ² (35)	-	-	46	46	100	100	100	-	-	-	-	-

1. Relative Total Cost per Day PO/IV for Treatment: Green = Least expense, Red = Most expense
2. Trend assessment not provided due to low number of isolates.
3. Cannot differentiate Cefazolin Susceptible from Intermediate categories by testing method on non urinary tract specimens. Results valid only when used as therapy for uncomplicated UTI.
4. For serious enterococcal infections, combination therapy with a beta lactam and an aminoglycoside should be used. *E. faecium* data are based on first isolate per patient within calendar year.
5. Due to low number of isolates, reported as actual number of isolates susceptible.